Yeen Hernández, national promoter of the drug from the Center for Genetic Engineering and Biotechnology (CIGB), explained that the province has achieved commendable results for several years, and in 2016 maintained the integrality in all indicators, with an increase above 26, 9 percent in the inclusion of new patients.
Research for the early detection of DFU was decisive in reducing the number of amputations: only seven were recorded, demonstrating the effectiveness of the drug and the quality of the attention in primary health care institutions.
Hernández insisted on the importance of prevention to avoid complications of diabetes mellitus. At the same time he urged the professionals to continue the systematic labor and maintain the cohesion of the work team that make this program an example of good practices within the sector.
More than 60,000 Cubans have been treated with Heberprot-P from 2006 to date. The drug, unique of its type, is registered in more than 30 nations, and its application is consolidated in Venezuela and Ecuador.
Escriba su comentario
Post comentado como Invitado